Imexpharm Balance Sheet Health
Financial Health criteria checks 6/6
Imexpharm has a total shareholder equity of ₫2,150.1B and total debt of ₫104.2B, which brings its debt-to-equity ratio to 4.8%. Its total assets and total liabilities are ₫2,581.7B and ₫431.6B respectively. Imexpharm's EBIT is ₫356.7B making its interest coverage ratio -64.7. It has cash and short-term investments of ₫270.4B.
Key information
4.8%
Debt to equity ratio
₫104.19b
Debt
| Interest coverage ratio | -64.7x |
| Cash | ₫270.41b |
| Equity | ₫2.15t |
| Total liabilities | ₫431.59b |
| Total assets | ₫2.58t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IMP's short term assets (₫1,466.8B) exceed its short term liabilities (₫431.6B).
Long Term Liabilities: IMP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMP has more cash than its total debt.
Reducing Debt: IMP's debt to equity ratio has reduced from 6.9% to 4.8% over the past 5 years.
Debt Coverage: IMP's debt is well covered by operating cash flow (229.6%).
Interest Coverage: IMP earns more interest than it pays, so coverage of interest payments is not a concern.